At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
Paxman Scalp Cooling Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Hair Loss Prevention Study for Patients With Advanced Pancreatic Cancer Utilizing Scalp Cooling
In Brief
A clinical study evaluating Paxman Scalp Cooling Device for Alopecia. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedJul 2020
Primary CompletionApr 2021
Study CompletionDec 2021
TodayJul 2026
First PostedJul 30, 2020
Enrollment StartDec 13, 2019
Primary CompletionApr 20, 2021
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.9 years ago
Interventions
Paxman Scalp Cooling Devicedevice
Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).